Sage Therapeutics(US:SAGE)2024-04-25 16:04ZURZUVAE Launch & Market Access - Over 1,200 prescriptions of ZURZUVAE have been written[15] - More than 700 prescriptions of ZURZUVAE have been shipped/delivered[20] - OBGYNs accounted for the largest share of ZURZUVAE prescriptions, followed by psychiatrists and PCPs[20] - Over 65% of commercial lives are covered by payor policies in PPD with the majority having no step therapy or complex prior authorization for ZURZUVAE[20] Clinical Development Pipeline - Phase 2 data for dalzanemdor (SAGE-718) in Huntington's Disease (HD) and Alzheimer's Disease (AD) indications is expected in 2024[23] - Topline data from the SURVEYOR Study in HD is expected in mid-2024[25] - Topline data from the LIGHTWAVE Study in AD is expected in late 2024[25] - Topline data from the DIMENSION Study in HD is expected in late 2024[25] - Topline data from Phase 2 KINETIC 2 Study in Essential Tremor (ET) for SAGE-324 is expected in mid-2024[39] Financial Position - Sage Therapeutics reported a strong financial position with $717 million in cash at the end of Q1 2024[36] - Total revenue for Q1 2024 was $7.9 million, compared to $3.3 million in Q1 2023[36] - Net loss for Q1 2024 was ($108.5 million), compared to ($146.8 million) for Q1 2023[36]